Back to Research Home
ICLRICON PLC
Health Care · Biotechnology: Commercial Physical & Biological Resarch · Large
$185.27−0.09%
As of 23 Oct 2026Mkt cap $12.3B
Stage 13
AVOID
Fundamentals
31.8/75
Technical
6.3/15
Independent
38.0/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +6.5%
- 3M
- +9.8%
- 6M
- +81.3%
- 1Y
- −3.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 330.8xHist median 34.8x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 16.6x
- FCF yield
- 6.0%
Quality
- ROIC
- 3.3%
- Operating margin
- 11.2%
- FCF margin
- 10.4%
- Current ratio
- 1.1x
Growth
- Revenue growth
- +0.8%Latest FY YoY
- Revenue CAGR
- +10.8%
- EPS CAGR
- +6.5%
- FCF CAGR
- +4.1%
Capital
- Share-count trend
- −2.3%3Y annualised
- Net debt
- $2.8B2.7x OCF
Annual trend
- CAGR 2021–2025
- +10.8%
- Latest · 2025
- $8B
- YoY
- +0.8%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL DECELERATION
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-27
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded